Pinar Alper
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Pinar Alper has a total of 185 co-authors. Here are the top co-authors by number of shared publications:
- Carole Goble
The Department of Computer Science, the University of Manchester, Manchester, United Kingdom
5 shared publications - Reinhard Schneider
University of Luxembourg
4 shared publications Jacek Lebioda
Luxembourg National Data Service, PNED GIE, Esch-sur-Alzette, Luxembourg
3 shared publications- Khalid Belhajjame
Université Paris-Dauphine, PSL Research University CNRS UMR [7243] LAMSADE
3 shared publications Regina Becker
Luxembourg National Data Service, PNED GIE, Esch-sur-Alzette, Luxembourg
3 shared publications- Venkata Satagopam
Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Belvaux, Luxembourg
3 shared publications
Latest Publications
- Open Access
- 26 November 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-22
Multiomics approaches disclose very-early molecular and cellular switches during insect-venom allergen-specific immunotherapy: an observational study
Allergen-specific immunotherapy (AIT) induces immune tolerance, showing the highest success rate (>95%) for insect venom while a much lower chance for pollen allergy. However, the molecular switches leading to successful durable tolerance restoration remain elusive. The primary outcome of this observational study is the comprehensive immunological cellular characterization during the AIT initiation phase, whereas the secondary outcomes are the serological and Th2-cell-type-specific transcriptomic analyses. Here we apply a multilayer-omics approach to reveal dynamic peripheral immune landscapes during the AIT-initiation phase in venom allergy patients (VAP) versus pollen-allergic and healthy controls. Already at baseline, VAP exhibit altered abundances of several cell types, including classical monocytes (cMono), CD4+ hybrid type 1-type 17 cells (Th1-Th17 or Th1/17) and CD8+ counterparts (Tc1-Tc17 or Tc1/17). At 8-24 h following AIT launch in VAP, we identify a uniform AIT-elicited pulse of late-transitional/IL-10-producing B cells, IL-6 signaling within Th2 cells and non-inflammatory serum-IL-6 levels. Sequential induction of activation and survival protein markers also immediately occur. A disequilibrium between serum IL-6 and cMono in VAP baseline is restored at day seven following AIT launch. Our longitudinal analysis discovers molecular switches during initiation-phase insect-venom AIT that secure long-term outcomes. Trial number: NCT02931955.
- 26 November 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-22
Open AccessMultiomics approaches disclose very-early molecular and cellular switches during insect-venom allergen-specific immunotherapy: an observational study
Allergen-specific immunotherapy (AIT) induces immune tolerance, showing the highest success rate (>95%) for insect venom while a much lower chance for pollen allergy. However, the molecular switches leading to successful durable tolerance restoration remain elusive. The primary outcome of this observational study is the comprehensive immunological cellular characterization during the AIT initiation phase, whereas the secondary outcomes are the serological and Th2-cell-type-specific transcriptomic analyses. Here we apply a multilayer-omics approach to reveal dynamic peripheral immune landscapes during the AIT-initiation phase in venom allergy patients (VAP) versus pollen-allergic and healthy controls. Already at baseline, VAP exhibit altered abundances of several cell types, including classical monocytes (cMono), CD4+ hybrid type 1-type 17 cells (Th1-Th17 or Th1/17) and CD8+ counterparts (Tc1-Tc17 or Tc1/17). At 8-24 h following AIT launch in VAP, we identify a uniform AIT-elicited pulse of late-transitional/IL-10-producing B cells, IL-6 signaling within Th2 cells and non-inflammatory serum-IL-6 levels. Sequential induction of activation and survival protein markers also immediately occur. A disequilibrium between serum IL-6 and cMono in VAP baseline is restored at day seven following AIT launch. Our longitudinal analysis discovers molecular switches during initiation-phase insect-venom AIT that secure long-term outcomes. Trial number: NCT02931955.
- Open Access
- 15 May 2024
- Published by Springer Nature in Scientific Data
- Vol. 11 (1) , 1-11
DS-PACK: Tool assembly for the end-to-end support of controlled access human data sharing
The EU General Data Protection Regulation (GDPR) requirements have prompted a shift from centralised controlled access genome-phenome archives to federated models for sharing sensitive human data. In a data-sharing federation, a central node facilitates data discovery; meanwhile, distributed nodes are responsible for handling data access requests, concluding agreements with data users and providing secure access to the data. Research institutions that want to become part of such federations often lack the resources to set up the required controlled access processes. The DS-PACK tool assembly is a reusable, open-source middleware solution that semi-automates controlled access processes end-to-end, from data submission to access. Data protection principles are engraved into all components of the DS-PACK assembly. DS-PACK centralises access control management and distributes access control enforcement with support for data access via cloud-based applications. DS-PACK is in production use at the ELIXIR Luxembourg data hosting platform, combined with an operational model including legal facilitation and data stewardship.
- 15 May 2024
- Published by Springer Nature in Scientific Data
- Vol. 11 (1) , 1-11
Open AccessDS-PACK: Tool assembly for the end-to-end support of controlled access human data sharing
The EU General Data Protection Regulation (GDPR) requirements have prompted a shift from centralised controlled access genome-phenome archives to federated models for sharing sensitive human data. In a data-sharing federation, a central node facilitates data discovery; meanwhile, distributed nodes are responsible for handling data access requests, concluding agreements with data users and providing secure access to the data. Research institutions that want to become part of such federations often lack the resources to set up the required controlled access processes. The DS-PACK tool assembly is a reusable, open-source middleware solution that semi-automates controlled access processes end-to-end, from data submission to access. Data protection principles are engraved into all components of the DS-PACK assembly. DS-PACK centralises access control management and distributes access control enforcement with support for data access via cloud-based applications. DS-PACK is in production use at the ELIXIR Luxembourg data hosting platform, combined with an operational model including legal facilitation and data stewardship.
- Open Access
- 8 May 2024
- Published by Springer Nature in Scientific Data
- Vol. 11 (1) , 1-10
Getting your DUCs in a row - standardising the representation of Digital Use Conditions
Improving patient care and advancing scientific discovery requires responsible sharing of research data, healthcare records, biosamples, and biomedical resources that must also respect applicable use conditions. Defining a standard to structure and manage these use conditions is a complex and challenging task. This is exemplified by a near unlimited range of asset types, a high variability of applicable conditions, and differing applications at the individual or collective level. Furthermore, the specifics and granularity required are likely to vary depending on the ultimate contexts of use. All these factors confound alignment of institutional missions, funding objectives, regulatory and technical requirements to facilitate effective sharing. The presented work highlights the complexity and diversity of the problem, reviews the current state of the art, and emphasises the need for a flexible and adaptable approach. We propose Digital Use Conditions (DUC) as a framework that addresses these needs by leveraging existing standards, striking a balance between expressiveness versus ambiguity, and considering the breadth of applicable information with their context of use.
- 8 May 2024
- Published by Springer Nature in Scientific Data
- Vol. 11 (1) , 1-10
Open AccessGetting your DUCs in a row - standardising the representation of Digital Use Conditions
Improving patient care and advancing scientific discovery requires responsible sharing of research data, healthcare records, biosamples, and biomedical resources that must also respect applicable use conditions. Defining a standard to structure and manage these use conditions is a complex and challenging task. This is exemplified by a near unlimited range of asset types, a high variability of applicable conditions, and differing applications at the individual or collective level. Furthermore, the specifics and granularity required are likely to vary depending on the ultimate contexts of use. All these factors confound alignment of institutional missions, funding objectives, regulatory and technical requirements to facilitate effective sharing. The presented work highlights the complexity and diversity of the problem, reviews the current state of the art, and emphasises the need for a flexible and adaptable approach. We propose Digital Use Conditions (DUC) as a framework that addresses these needs by leveraging existing standards, striking a balance between expressiveness versus ambiguity, and considering the breadth of applicable information with their context of use.
- Open Access
- 22 February 2024
- Published by Springer Nature in Research Square
Multiomics approaches disclose very-early molecular and cellular switches during insect-venom allergen-specific immunotherapy
Allergen-specific immunotherapy (AIT) induces immune tolerance, showing the highest success rate (>95%) for insect venom while a much lower chance for pollen allergy. However, the molecular switches leading to successful durable tolerance restoration remain elusive. Here we applied a multilayer-omics approach to reveal dynamic peripheral immune landscapes during AIT-initiation phase in venom allergy patients (VAP) versus pollen-allergic and healthy controls. Already at baseline, VAP exhibited altered abundances of several cell types, including antigen-presenting cells (APC) and hybrid types, especially pDC-mDC hybrids. At 8-24h following AIT launch in VAP, we identified a uniform AIT-elicited pulse of late-transitional/IL-10-producing B cells, IL-6 signaling within Th2 cells and non-inflammatory serum-IL-6 levels. Sequential induction of activation and survival protein markers also immediately occurred. A disequilibrium between serum IL-6 and APC in VAP baseline was restored at day seven following AIT launch. Our longitudinal analysis discovers molecular switches during initiation-phase insect-venom AIT that secure long-term outcomes.
- 22 February 2024
- Published by Springer Nature in Research Square
Open AccessMultiomics approaches disclose very-early molecular and cellular switches during insect-venom allergen-specific immunotherapy
Allergen-specific immunotherapy (AIT) induces immune tolerance, showing the highest success rate (>95%) for insect venom while a much lower chance for pollen allergy. However, the molecular switches leading to successful durable tolerance restoration remain elusive. Here we applied a multilayer-omics approach to reveal dynamic peripheral immune landscapes during AIT-initiation phase in venom allergy patients (VAP) versus pollen-allergic and healthy controls. Already at baseline, VAP exhibited altered abundances of several cell types, including antigen-presenting cells (APC) and hybrid types, especially pDC-mDC hybrids. At 8-24h following AIT launch in VAP, we identified a uniform AIT-elicited pulse of late-transitional/IL-10-producing B cells, IL-6 signaling within Th2 cells and non-inflammatory serum-IL-6 levels. Sequential induction of activation and survival protein markers also immediately occurred. A disequilibrium between serum IL-6 and APC in VAP baseline was restored at day seven following AIT launch. Our longitudinal analysis discovers molecular switches during initiation-phase insect-venom AIT that secure long-term outcomes.
- Open Access
- 7 September 2023
- Published by TIB Open Publishing in Proceedings of the Conference on Research Data Infrastructure
- Vol. 1
RDMkit: The Research Data Management Toolkit for Life Sciences
Effective data management extends over the entire life cycle of data, from the point of creation through to dissemination and archiving, and usually continues long after a research project is concluded. Tailored guidance for management of research data is increasing its importance among data-driven scientific investigations. There is now increasing demand for Research Data Management (RDM), by funders and host institutions, for researchers to develop and implement data management plans for projects. The RDMkit, by ELIXIR Europe, is an open community-led resource designed to share knowledge on how to carry out RDM in life sciences research. It fills the training and learning gap by providing knowledge on domain-focused RDM considerations, task-focused solutions and resources, and tool assemblies that showcase real-life examples addressing how combinations of tools can be used to go through the data life cycle. The technical infrastructure of the RDMkit is reproducible, making it possible for other organisations to use the structure as a guide and inspiration to set up RDM source for their users. In this talk, RDMkit will be introduced with example best practice guidelines, and integrations and knowledge sources.
- 7 September 2023
- Published by TIB Open Publishing in Proceedings of the Conference on Research Data Infrastructure
- Vol. 1
Open AccessRDMkit: The Research Data Management Toolkit for Life Sciences
Effective data management extends over the entire life cycle of data, from the point of creation through to dissemination and archiving, and usually continues long after a research project is concluded. Tailored guidance for management of research data is increasing its importance among data-driven scientific investigations. There is now increasing demand for Research Data Management (RDM), by funders and host institutions, for researchers to develop and implement data management plans for projects. The RDMkit, by ELIXIR Europe, is an open community-led resource designed to share knowledge on how to carry out RDM in life sciences research. It fills the training and learning gap by providing knowledge on domain-focused RDM considerations, task-focused solutions and resources, and tool assemblies that showcase real-life examples addressing how combinations of tools can be used to go through the data life cycle. The technical infrastructure of the RDMkit is reproducible, making it possible for other organisations to use the structure as a guide and inspiration to set up RDM source for their users. In this talk, RDMkit will be introduced with example best practice guidelines, and integrations and knowledge sources.
- Open Access
- 20 July 2023
- Published by Springer Nature in Scientific Data
- Vol. 10 (1) , 1-9
The Translational Data Catalog - discoverable biomedical datasets
The discoverability of datasets resulting from the diverse range of translational and biomedical projects remains sporadic. It is especially difficult for datasets emerging from pre-competitive projects, often due to the legal constraints of data-sharing agreements, and the different priorities of the private and public sectors. The Translational Data Catalog is a single discovery point for the projects and datasets produced by a number of major research programmes funded by the European Commission. Funded by and rooted in a number of these European private-public partnership projects, the Data Catalog is built on FAIR-enabling community standards, and its mission is to ensure that datasets are findable and accessible by machines. Here we present its creation, content, value and adoption, as well as the next steps for sustainability within the ELIXIR ecosystem.
- 20 July 2023
- Published by Springer Nature in Scientific Data
- Vol. 10 (1) , 1-9
Open AccessThe Translational Data Catalog - discoverable biomedical datasets
The discoverability of datasets resulting from the diverse range of translational and biomedical projects remains sporadic. It is especially difficult for datasets emerging from pre-competitive projects, often due to the legal constraints of data-sharing agreements, and the different priorities of the private and public sectors. The Translational Data Catalog is a single discovery point for the projects and datasets produced by a number of major research programmes funded by the European Commission. Funded by and rooted in a number of these European private-public partnership projects, the Data Catalog is built on FAIR-enabling community standards, and its mission is to ensure that datasets are findable and accessible by machines. Here we present its creation, content, value and adoption, as well as the next steps for sustainability within the ELIXIR ecosystem.
- Open Access
- 15 June 2023
- Published by Center for Open Science in BioHackrXiv
BioHackEU22 Report for Project 31: The What & How in data management: Improving connectivity between RDMkit and FAIR Cookbook
This report describes the work completed during the ELIXIR Biohackathon 2022 for project 31: The What & How in data management: Improving connectivity between RDMkit and FAIR Cookbook. The project covered 3 subjects: the technical connectivity between the two primary resources, an editorial alignment and gap analysis of their content, and the creation of user journeys incorporating the wider ELIXIR Research Data Management (RDM) ecosystem.
- 15 June 2023
- Published by Center for Open Science in BioHackrXiv
Open AccessBioHackEU22 Report for Project 31: The What & How in data management: Improving connectivity between RDMkit and FAIR Cookbook
This report describes the work completed during the ELIXIR Biohackathon 2022 for project 31: The What & How in data management: Improving connectivity between RDMkit and FAIR Cookbook. The project covered 3 subjects: the technical connectivity between the two primary resources, an editorial alignment and gap analysis of their content, and the creation of user journeys incorporating the wider ELIXIR Research Data Management (RDM) ecosystem.
- Open Access
- 10 November 2021
- Published by Elsevier in Cell Genomics
- Vol. 1 (2)
GA4GH Passport standard for digital identity and access permissions
- 10 November 2021
- Published by Elsevier in Cell Genomics
- Vol. 1 (2)
Open AccessGA4GH Passport standard for digital identity and access permissions
- Top Cited PapersOpen Access
- 10 November 2021
- Published by Elsevier in Cell Genomics
- Vol. 1 (2)
The Data Use Ontology to streamline responsible access to human biomedical datasets
- 10 November 2021
- Published by Elsevier in Cell Genomics
- Vol. 1 (2)
Top Cited PapersOpen AccessThe Data Use Ontology to streamline responsible access to human biomedical datasets
- Open Access
- 1 December 2019
- Published by Oxford University Press (OUP) in GigaScience
- Vol. 8 (12)
DAISY: A Data Information System for accountability under the General Data Protection Regulation
Background: The new European legislation on data protection, namely, the General Data Protection Regulation (GDPR), has introduced comprehensive requirements for the documentation about the processing of personal data as well as informing the data subjects of its use. GDPR's accountability principle requires institutions, projects, and data hubs to document their data processings and demonstrate compliance with the GDPR. In response to this requirement, we see the emergence of commercial data-mapping tools, and institutions creating GDPR data register with such tools. One shortcoming of this approach is the genericity of tools, and their process-based model not capturing the project-based, collaborative nature of data processing in biomedical research. Findings: We have developed a software tool to allow research institutions to comply with the GDPR accountability requirement and map the sometimes very complex data flows in biomedical research. By analysing the transparency and record-keeping obligations of each GDPR principle, we observe that our tool effectively meets the accountability requirement. Conclusions: The GDPR is bringing data protection to center stage in research data management, necessitating dedicated tools, personnel, and processes. Our tool, DAISY, is tailored specifically for biomedical research and can help institutions in tackling the documentation challenge brought about by the GDPR. DAISY is made available as a free and open source tool on Github. DAISY is actively being used at the Luxembourg Centre for Systems Biomedicine and the ELIXIR-Luxembourg data hub.
- 1 December 2019
- Published by Oxford University Press (OUP) in GigaScience
- Vol. 8 (12)
Open AccessDAISY: A Data Information System for accountability under the General Data Protection Regulation
Background: The new European legislation on data protection, namely, the General Data Protection Regulation (GDPR), has introduced comprehensive requirements for the documentation about the processing of personal data as well as informing the data subjects of its use. GDPR's accountability principle requires institutions, projects, and data hubs to document their data processings and demonstrate compliance with the GDPR. In response to this requirement, we see the emergence of commercial data-mapping tools, and institutions creating GDPR data register with such tools. One shortcoming of this approach is the genericity of tools, and their process-based model not capturing the project-based, collaborative nature of data processing in biomedical research. Findings: We have developed a software tool to allow research institutions to comply with the GDPR accountability requirement and map the sometimes very complex data flows in biomedical research. By analysing the transparency and record-keeping obligations of each GDPR principle, we observe that our tool effectively meets the accountability requirement. Conclusions: The GDPR is bringing data protection to center stage in research data management, necessitating dedicated tools, personnel, and processes. Our tool, DAISY, is tailored specifically for biomedical research and can help institutions in tackling the documentation challenge brought about by the GDPR. DAISY is made available as a free and open source tool on Github. DAISY is actively being used at the Luxembourg Centre for Systems Biomedicine and the ELIXIR-Luxembourg data hub.